Concerning the evaluation of endocrine disorders and islet cell transplantation: The progress in stem cell that includes the possibility of autogenous source, if and when the generation of islet cells is achieved, type 1 diabetes may be transiently or permanently improved, with a possibility of sustained normalization of glucose control and arrest of progression of diabetic complications; with some reversal of some complications. Autogenous islet cells will remain a target of autoimmune attack, likely requiring prevention of rejection measures, akin to measures currently offered to potential type- 1 diabetics with less than full protection at present level of success. Other than the cost of obtaining and deriving stem cells to islet cell development, there are no problems in the trying; only potential gains. No need to change endocrine listings, except perhaps for the potential adverse effect of the immune suppression.
Idea No. 94